Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms
- PMID: 28389504
- DOI: 10.1530/ERC-17-0091
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms
Abstract
The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been shown to associate with several tissue- and blood-based biomarkers in different settings. The identification of prognostic factors predicting NEN outcome is of paramount importance to select the best clinical management for these patients. Prognostic markers have been intensively investigated, also taking advantage of the most modern techniques, in the perspective of personalized medicine and appropriate resource utilization. This review summarizes the available data on the possible role of circulating tumor cells and microRNAs as prognostic markers in NENs.
Keywords: CTC; circulating biomarkers; miRNA; neuroendocrine tumors; prognosis.
© 2017 Society for Endocrinology.
Similar articles
-
Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs.Endocrinol Metab Clin North Am. 2018 Sep;47(3):471-483. doi: 10.1016/j.ecl.2018.04.002. Epub 2018 Jul 11. Endocrinol Metab Clin North Am. 2018. PMID: 30098711 Review.
-
[Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Mar 25;20(3):357-360. Zhonghua Wei Chang Wai Ke Za Zhi. 2017. PMID: 28338171 Review. Chinese.
-
Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?Front Endocrinol (Lausanne). 2021 Jul 22;12:672499. doi: 10.3389/fendo.2021.672499. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34367064 Free PMC article. Review.
-
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.Endocr Relat Cancer. 2018 Jan;25(1):R11-R29. doi: 10.1530/ERC-17-0269. Epub 2017 Oct 24. Endocr Relat Cancer. 2018. PMID: 29066503 Review.
-
Consensus on biomarkers for neuroendocrine tumour disease.Lancet Oncol. 2015 Sep;16(9):e435-e446. doi: 10.1016/S1470-2045(15)00186-2. Lancet Oncol. 2015. PMID: 26370353 Free PMC article. Review.
Cited by
-
Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.Nat Rev Endocrinol. 2020 Oct;16(10):590-607. doi: 10.1038/s41574-020-0391-3. Epub 2020 Aug 24. Nat Rev Endocrinol. 2020. PMID: 32839579 Review.
-
Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.Cancers (Basel). 2019 Sep 8;11(9):1332. doi: 10.3390/cancers11091332. Cancers (Basel). 2019. PMID: 31500357 Free PMC article. Review.
-
A tool to predict survival in stage IV entero-pancreatic NEN.J Endocrinol Invest. 2021 Jun;44(6):1185-1192. doi: 10.1007/s40618-020-01404-4. Epub 2020 Sep 6. J Endocrinol Invest. 2021. PMID: 32892316 Free PMC article.
-
Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.Int J Mol Sci. 2022 Jan 20;23(3):1109. doi: 10.3390/ijms23031109. Int J Mol Sci. 2022. PMID: 35163032 Free PMC article. Review.
-
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.Front Oncol. 2022 Feb 4;12:780716. doi: 10.3389/fonc.2022.780716. eCollection 2022. Front Oncol. 2022. PMID: 35186729 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources